Nyxoah S.A. (NYXH)
| Bid | 4.94 |
| Market Cap | 207.52M |
| Revenue (ttm) | 4.52M |
| Net Income (ttm) | -59.24M |
| EPS (ttm) | -2.04 |
| PE Ratio (ttm) | -2.96 |
| Forward PE | -3.45 |
| Analyst | Buy |
| Ask | 6.6 |
| Volume | 76,629 |
| Avg. Volume (20D) | 117,022 |
| Open | 5.98 |
| Previous Close | 6.02 |
| Day's Range | 5.93 - 6.09 |
| 52-Week Range | 5.55 - 12.21 |
| Beta | 0.65 |
About NYXH
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium....
Analyst Forecast
According to 4 analyst ratings, the average rating for NYXH stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 148.55% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago · accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHNEW YORK, NY / ACCESS Newswire / April 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH).
